CD44/JAK2/STAT3 signaling pathway

Overview

The CD44/JAK2/STAT3 signaling pathway is a cell-signaling axis centered on the transmembrane adhesion receptor CD44 and the intracellular kinases/transcription factors JAK2 and STAT3. In biomedical research, this pathway is commonly discussed as a regulator of cell survival, proliferation, inflammatory signaling, stem-like phenotypes, immune-cell polarization, and tumor progression. CD44 is frequently implicated in hyaluronan-dependent cell interactions and tumor microenvironment signaling, while JAK2-mediated phosphorylation of STAT3 can drive transcriptional programs associated with inflammation and malignancy.

In recent literature, this pathway has been studied in cancer and inflammatory disease contexts, including thyroid cancer, pancreatic cancer, glioblastoma, acute myeloid leukemia, acute lymphoblastic leukemia, psoriasis, cutaneous T-cell lymphoma, and acute lung injury. It also appears in mechanistic studies of natural products and combination therapies that modulate IL-6/JAK2/STAT3, JAK2/STAT3, or CD44-linked signaling, often alongside related pathways such as PI3K/Akt signaling pathway, PI3K/AKT/mTOR pathway, TGFB1, interleukin-6, KRAS, and STAT5A.

Focus of Latest Publications

Recent studies have established JAK2/STAT3 signaling as a critical and therapeutically tractable node across malignancies and inflammatory disease. In non-small cell lung cancer, novel butein derivatives achieved dual targeting of EGFR kinase and downstream JAK2/STAT3 signaling, inducing G2/M cell cycle arrest and apoptosis in A549 cells and successfully suppressing oncogenic activation in gefitinib-resistant models. In pancreatic ductal adenocarcinoma, combination therapy simultaneously inhibiting STAT3 alongside Kras and EGFR achieved complete and durable tumor regression in orthotopic models and patient-derived xenografts with no evidence of therapeutic resistance sustained over 200 days posttreatment. In gastric cancer, ginkgetin suppressed STAT3 phosphorylation to induce immunogenic cell death in malignant cells while reversing the immunosuppressive tumor microenvironment and activating anti-tumor immunity.

CD44-enriched cancers have emerged as particularly susceptible to JAK2/STAT3-targeted approaches. Pancreatic cancer cells overexpressing CD44 were therapeutically targeted both via CD44-functionalized nanoparticles and through direct JAK2/STAT3 inhibition, and mechanistic studies identified CD44 as a chondroitin sulfate proteoglycan core protein that masks HER2 and functions as a glycan-mediated therapeutic resistance mechanism. These findings suggest that CD44-expressing cancer stem cells may be uniquely dependent on STAT3 signaling for maintenance of stemness and chemoresistance.

JAK2/STAT3 pathway suppression has proven efficacious in inflammatory and immune dysregulation contexts. In sepsis, combined moxibustion and anti-PD-1 antibody therapy synergistically suppressed STAT3 expression and nuclear translocation, reversing immunosuppression through the PD-1/PD-L1/STAT3 axis and restoring T cell proportions and function. Traditional herbal formulas suppressed JAK2/STAT3 signaling in blood deficiency syndrome via IL-6 pathway inhibition and in psoriasis by rebalancing Th17/Treg responses. In sepsis-associated acute kidney injury, a CD44-targeted nanozyme modulating the SIRT3/RORγt/STAT3 pathway simultaneously suppressed Th17-driven inflammation and restored mitochondrial homeostasis. Mechanistically, the fungal metabolite IM502 redirected STAT3 signaling from pro-inflammatory STAT3/6 to pro-antiviral STAT1/2 pathways, thereby reprogramming tumor-associated macrophage phenotype and enhancing NK and CD8+ T cell function. Collectively, these studies establish JAK2/STAT3 and CD44-expressing cellular populations as conserved therapeutic nodes in both oncologic and inflammatory pathologies.